Firebrick Pharma (ASX:FRE) Equity-to-Asset : 0.82 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Firebrick Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$1.59 Mil. Firebrick Pharma's Total Assets for the quarter that ended in Dec. 2023 was A$1.95 Mil. Therefore, Firebrick Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.82.

The historical rank and industry rank for Firebrick Pharma's Equity-to-Asset or its related term are showing as below:

ASX:FRE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.82 Med: 0.87 Max: 0.95
Current: 0.82

During the past 3 years, the highest Equity to Asset Ratio of Firebrick Pharma was 0.95. The lowest was 0.82. And the median was 0.87.

ASX:FRE's Equity-to-Asset is ranked better than
84.48% of 1089 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs ASX:FRE: 0.82

Firebrick Pharma Equity-to-Asset Historical Data

The historical data trend for Firebrick Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Equity-to-Asset Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Equity-to-Asset

0.98

0.95

0.83

Firebrick Pharma Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	0.95	0.91	0.83	0.82

Competitive Comparison of Firebrick Pharma's Equity-to-Asset

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Firebrick Pharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Equity-to-Asset falls into.

Firebrick Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Firebrick Pharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2.476	/	2.982
	=	0.83

Firebrick Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1.589	/	1.945
	=	0.82

Firebrick Pharma (ASX:FRE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Firebrick Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma (ASX:FRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines